GeneFerm Biotechnology Co Ltd Cash Flow-to-Debt Ratio
GeneFerm Biotechnology Co Ltd cash flow-to-debt ratio. GeneFerm Biotechnology Co Ltd (1796) has a Cash Flow-to-Debt Ratio of 0.00x as of June 2025, meaning its operating cash flow of NT$1.45 Million could theoretically repay 0% of its total liabilities (NT$453.10 Million) in one year. Check GeneFerm Biotechnology Co Ltd cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of GeneFerm Biotechnology Co Ltd (2017–2024)
Cash flow-to-debt ratio of GeneFerm Biotechnology Co Ltd from 2017 to 2024. Historical debt coverage capacity for GeneFerm Biotechnology Co Ltd across 8 annual periods. Check GeneFerm Biotechnology Co Ltd (1796) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
GeneFerm Biotechnology Co Ltd Cash Flow-to-Debt Ratio by Year (2017–2024)
GeneFerm Biotechnology Co Ltd cash flow-to-debt ratio by year from 2017 to 2024. Year-by-year debt coverage analysis for GeneFerm Biotechnology Co Ltd. For the full cash flow conversion analysis, see cash flow conversion of GeneFerm Biotechnology Co Ltd.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.02x | NT$8.09 Million | NT$358.31 Million | ▼ -96.6% |
| 2023 | 0.67x | NT$190.31 Million | NT$282.54 Million | ▲ +97.4% |
| 2022 | 0.34x | NT$122.43 Million | NT$358.86 Million | ▲ +73.0% |
| 2021 | 0.20x | NT$112.23 Million | NT$569.22 Million | ▲ +104.9% |
| 2020 | 0.10x | NT$56.42 Million | NT$586.38 Million | ▼ -69.9% |
| 2019 | 0.32x | NT$14.69 Million | NT$46.00 Million | ▲ +6.6% |
| 2018 | 0.30x | NT$42.14 Million | NT$140.69 Million | ▼ -5.0% |
| 2017 | 0.32x | NT$61.08 Million | NT$193.79 Million | — |